前列腺癌雄激素受体靶向药物的心血管风险:系统评价与Meta分析
该系统评价与Meta分析通过检索三个数据库,评估前列腺癌患者使用雄激素受体靶向药物(ARTA)对比安慰剂后心脏相关不良事件的发生率差异。结果显示ARTA增加心脏相关不良事件(RR 1.56,95%CI 1.29-1.90,p<0.00001)、高血压(RR 1.69,95%CI 1.46-1.97,p<0.00001)、缺血性心脏病(RR 1.84,95%CI 1.36-2.50,p<0.0001)和心律失常(RR 1.38,95%CI 1.11-1.71,p=0.004)的发生率,但心脏骤停/死亡发生率未显著增加(RR 1.28,95%CI 0.87-1.88,p=0.21)。作者认为了解这些风险有助于管理心脏风险并在启动ARTA时按需请心脏科会诊。
要点
- 前列腺癌使用ARTA增加心脏相关不良事件风险(RR 1.56,95%CI 1.29-1.90,p<0.00001)。
- ARTA增加高血压(RR 1.69)、缺血性心脏病(RR 1.84)和心律失常(RR 1.38)风险。
- 心脏骤停/死亡发生率未显著增加(RR 1.28,95%CI 0.87-1.88,p=0.21)。
核心结论
- ARTA增加心脏相关不良事件、高血压、缺血性心脏病和心律失常的风险。
- 作者认为掌握这些信息有助于相应管理心脏风险,并在启动ARTA时按需请心脏科会诊。
研究设计与样本
- 系统评价与Meta分析,检索三个数据库,采用PICOS模型构建临床问题,由2名独立作者经多轮筛选确定最终纳入研究。
- Meta分析采用Cochran-Mantel-Haenszel法,质量评估采用Cochrane偏倚风险工具RoB 2。
主要发现
- 前列腺癌使用ARTA增加心脏相关不良事件发生率(RR 1.56,95%CI 1.29-1.90,p<0.00001)。
- ARTA增加高血压发生率(RR 1.69,95%CI 1.46-1.97,p<0.00001)。
- ARTA增加缺血性心脏病发生率(RR 1.84,95%CI 1.36-2.50,p<0.0001)。
- ARTA增加心律失常发生率(RR 1.38,95%CI 1.11-1.71,p=0.004)。
- 心脏骤停/死亡发生率未显著增加(RR 1.28,95%CI 0.87-1.88,p=0.21)。
临床怎么用
- 作者认为掌握ARTA的心脏风险信息有助于相应管理心脏风险,并在启动ARTA时按需请心脏科会诊。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Androgen receptor targeted agents (ARTA) have increasingly been incorporated into treatment regimens for various stages of prostate cancer. Patients are living longer with prostate cancer, and thus have a higher cumulative exposure to the treatment and its accompanying side effects, especially those of cardiovascular disease. We aim to assess the differences in the incidence of cardiac-related adverse events after treatment of prostate cancer with ARTA versus placebo. METHODS: Three databases were thoroughly searched for relevant articles. The PICOS model was used to frame our clinical question, with which 2 independent authors went through several rounds of screening to select the final included studies. Meta-analysis was done using the Cochran-Mantel-Haenszel Method. Quality assessment was carried out with the Cochrane Risk of Bias tool RoB 2. RESULTS: The use of ARTA in prostate cancer increases the incidence of cardiac-related adverse events (RR: 1.56, 95% CI: 1.29-1.90, p < 0.00001), such as hypertension (RR: 1.69, 95% CI: 1.46-1.97, p < 0.00001), ischaemic heart disease (RR: 1.84, 95% CI: 1.36-2.50, p < 0.0001), and arrhythmia (RR: 1.38, 95% CI: 1.11-1.71, p = 0.004), although this did not manifest in an increased incidence of cardiac arrests/deaths (RR: 1.28, 95% CI: 0.87-1.88, p = 0.21). DISCUSSION: ARTA increases the risk of cardiac-related adverse events, hypertension, ischaemic heart disease and arrhythmia. Armed with this knowledge, we will be better poised to manage cardiac risks accordingly and involve a cardiologist as required when starting patients on ARTA.
引用
- Ong CSH, Law YXT, Kyaw L, et al. Cardiovascular risks of androgen receptor targeted agents in prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2024. PMID: 38267540. doi:10.1038/s41391-024-00792-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。